An update of safety and efficacy results from phase 1 dose-escalation and expansion study of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI), in patients with chronic myeloid leukemia (CML) and philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) failing prior TKI therapies Meeting Abstract
| Authors: | Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Rathnam, K.; Khattry, N.; Apperley, J. F.; Deininger, M. W.; de Lavallade, H.; Charbonnier, A.; Granacher, N.; Gambacorti-Passerini, C.; Lucchesi, A.; Mauro, M. J.; Vandenberghe, P.; Verhoef, G.; Whiteley, A. R.; Nag, A.; Radhakrishnan, V. S.; Apte, S.; Yao, S. L.; Inamdar, S.; Sreenivasan, J.; Dillu, R. I.; Chimote, G. |
| Abstract Title: | An update of safety and efficacy results from phase 1 dose-escalation and expansion study of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI), in patients with chronic myeloid leukemia (CML) and philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) failing prior TKI therapies |
| Meeting Title: | 63nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398801086 |
| DOI: | 10.1182/blood-2021-152548 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 309 -- Hybrid meeting, also took place online -- Source: Wos |
